Provided by Tiger Trade Technology Pte. Ltd.

Agenus

8.09
+0.60008.01%
Post-market: 8.170.0800+0.99%19:45 EDT
Volume:1.52M
Turnover:12.14M
Market Cap:364.22M
PE:3.24
High:8.35
Open:7.58
Low:7.58
Close:7.49
52wk High:8.85
52wk Low:2.71
Shares:45.02M
Float Shares:42.21M
Volume Ratio:1.10
T/O Rate:3.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.83
PE(LYR):-2,382.21

Loading ...

MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million

Reuters
·
May 15

Agenus Buy Rating Reaffirmed as Late-Stage Strategy Advances; $23 Price Target Maintained

TIPRANKS
·
May 12

Agenus Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Agenus reports Q1 revenue $33.7M vs. $24.1M last year

TIPRANKS
·
May 11

Agenus provides 2026 strategic priorities

TIPRANKS
·
May 11

Agenus announces conclusion of SEC investigation with no enforcement action

TIPRANKS
·
May 11

Agenus Q1 Sales $33.700M May Not Be Comparable To $129.500M Estimate, Net Income Of $39.2M Vs. Loss of $26.4M YoY

Benzinga Earnings
·
May 11

Immuno-oncology developer Agenus' Q1 revenue rises, posts profit

Reuters
·
May 11

Press Release: Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Dow Jones
·
May 11

Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million

Reuters
·
May 11

Agenus Q1 Revenue USD 4.6 Million

THOMSON REUTERS
·
May 11

Corrected-Agenus Q1 Revenue USD 33.7 Million (Corrects Amount)

THOMSON REUTERS
·
May 11

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+Bal Execution Across Global Access and Phase 3 Development

THOMSON REUTERS
·
May 11

Agenus Inc expected to post earnings of $2.10 a share - Earnings Preview

Reuters
·
May 08

Agenus to report first-quarter results before market open

Reuters
·
May 05

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

THOMSON REUTERS
·
May 05

Agenus to present first Phase 2 botensilimab melanoma data at ASCO 2026

Reuters
·
Apr 21

Agenus names BAP Pharma exclusive global partner for botensilimab-balstilimab access programs

Reuters
·
Apr 21

Agenus announces annual shareholder meeting webcast

Reuters
·
Apr 21

Agenus reports Phase 2 results from BOT and BAL with agenT-797

TIPRANKS
·
Apr 18